Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a promising clinical-stage biotechnology company with a strong focus on developing treatments for age-related neurologic disorders. This is supported by their product candidate, Neflamapimod, which has shown potential to treat and improve synaptic dysfunction, the underlying disease process in DLB. The recent announcement of groundbreaking MRI analyses and biomarker data further reinforces the drug's potential and sets the stage for their Phase 3 trial initiation in 2026. With a promising pipeline, the company may see significant growth in the future, making it a sound investment opportunity.

Bears say

CervoMed is facing many risks, including limited funding for their planned Phase 3 trial, potential partnership and market share risks, and legal and intellectual property risks. While their recent MRI data and functional connectivity improvements are promising, the small dataset and lack of sufficient financing may hinder their progress in launching Neflamapimod for the treatment of dementia with Lewy bodies.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.